Elevance Health Q4 Adjusted EPS $5.62 Misses $5.64 Estimate, Sales $42.45B Beat $42.09B Estimate
Portfolio Pulse from Benzinga Newsdesk
Elevance Health (NYSE:ELV) reported Q4 adjusted EPS of $5.65, surpassing the $5.64 estimate, marking a 15.78% increase from last year's $4.88. Sales reached $42.45B, exceeding the $42.09B estimate, up 7.03% from the previous year.

January 24, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Elevance Health reported a positive earnings surprise with Q4 EPS of $5.65, beating estimates and showing significant year-over-year growth in both earnings and sales.
Elevance Health's earnings and sales beat not only indicates strong performance but also suggests the company is growing faster than expected. This positive earnings report is likely to instill investor confidence and could lead to a short-term increase in stock price, as beats on both top and bottom lines are typically well-received by the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100